Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma

Toshihiro Miyamoto, Goichi Yoshimoto, Tomohiko Kamimura, Tsuyoshi Muta, Shuichiro Takashima, Yoshikiyo Ito, Motoaki Shiratsuchi, Ilseung Choi, Koji Kato, Katsuto Takenaka, Hiromi Iwasaki, Yasushi Takamatsu, Takanori Teshima, Koichi Akashi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Bortezomib and melphalan have synergistic effects against multiple myeloma (MM) cells. We conducted a pilot study on the combination of bortezomib and high-dose melphalan (Bor-HDM) as a conditioning regimen followed by autologous stem cell transplant (ASCT) in 17 Japanese patients with newly diagnosed MM, in comparison with a historical control of patients who received high-dose melphalan (HDM) only followed by ASCT. Nine patients received a single dose of bortezomib 1.3 mg/m2 on day -1 in combination with melphalan 100 mg/m2 on days -3 and -2 (Bor1-HDM), and eight received two doses of bortezomib 1.3 mg/m2 on days -4 and -1 (Bor2-HDM) in combination with HDM. Engraftment of autologous peripheral blood stem cells and regimen-related toxicities (RRT) were comparable among the HDM and Bor-HDM groups. Probability of upgrading from a less than very good partial response (VGPR) to VGPR after ASCT was approximately two times higher in the Bor-HDM group than in the HDM group. However, we observed no significant differences in engraftment, RRT, and response rates between the Bor1-HDM and Bor2-HDM groups. The present study showed that concurrent administration of at least two doses of bortezomib in combination with HDM can be safe in Japanese patients. Additional large prospective randomized trials are required to address the optimal dosages and schedules of bortezomib administration, as well as the efficacy of the Bor-HDM conditioning regimen for ASCT.

Original languageEnglish
Pages (from-to)337-345
Number of pages9
JournalInternational journal of hematology
Volume98
Issue number3
DOIs
Publication statusPublished - Sep 1 2013

Fingerprint

Peripheral Blood Stem Cell Transplantation
Melphalan
Multiple Myeloma
Stem Cells
Transplants
Bortezomib

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. / Miyamoto, Toshihiro; Yoshimoto, Goichi; Kamimura, Tomohiko; Muta, Tsuyoshi; Takashima, Shuichiro; Ito, Yoshikiyo; Shiratsuchi, Motoaki; Choi, Ilseung; Kato, Koji; Takenaka, Katsuto; Iwasaki, Hiromi; Takamatsu, Yasushi; Teshima, Takanori; Akashi, Koichi.

In: International journal of hematology, Vol. 98, No. 3, 01.09.2013, p. 337-345.

Research output: Contribution to journalArticle

Miyamoto, Toshihiro ; Yoshimoto, Goichi ; Kamimura, Tomohiko ; Muta, Tsuyoshi ; Takashima, Shuichiro ; Ito, Yoshikiyo ; Shiratsuchi, Motoaki ; Choi, Ilseung ; Kato, Koji ; Takenaka, Katsuto ; Iwasaki, Hiromi ; Takamatsu, Yasushi ; Teshima, Takanori ; Akashi, Koichi. / Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. In: International journal of hematology. 2013 ; Vol. 98, No. 3. pp. 337-345.
@article{5c12944fc4da40bc8d664cff5e39cd4f,
title = "Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma",
abstract = "Bortezomib and melphalan have synergistic effects against multiple myeloma (MM) cells. We conducted a pilot study on the combination of bortezomib and high-dose melphalan (Bor-HDM) as a conditioning regimen followed by autologous stem cell transplant (ASCT) in 17 Japanese patients with newly diagnosed MM, in comparison with a historical control of patients who received high-dose melphalan (HDM) only followed by ASCT. Nine patients received a single dose of bortezomib 1.3 mg/m2 on day -1 in combination with melphalan 100 mg/m2 on days -3 and -2 (Bor1-HDM), and eight received two doses of bortezomib 1.3 mg/m2 on days -4 and -1 (Bor2-HDM) in combination with HDM. Engraftment of autologous peripheral blood stem cells and regimen-related toxicities (RRT) were comparable among the HDM and Bor-HDM groups. Probability of upgrading from a less than very good partial response (VGPR) to VGPR after ASCT was approximately two times higher in the Bor-HDM group than in the HDM group. However, we observed no significant differences in engraftment, RRT, and response rates between the Bor1-HDM and Bor2-HDM groups. The present study showed that concurrent administration of at least two doses of bortezomib in combination with HDM can be safe in Japanese patients. Additional large prospective randomized trials are required to address the optimal dosages and schedules of bortezomib administration, as well as the efficacy of the Bor-HDM conditioning regimen for ASCT.",
author = "Toshihiro Miyamoto and Goichi Yoshimoto and Tomohiko Kamimura and Tsuyoshi Muta and Shuichiro Takashima and Yoshikiyo Ito and Motoaki Shiratsuchi and Ilseung Choi and Koji Kato and Katsuto Takenaka and Hiromi Iwasaki and Yasushi Takamatsu and Takanori Teshima and Koichi Akashi",
year = "2013",
month = "9",
day = "1",
doi = "10.1007/s12185-013-1402-0",
language = "English",
volume = "98",
pages = "337--345",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma

AU - Miyamoto, Toshihiro

AU - Yoshimoto, Goichi

AU - Kamimura, Tomohiko

AU - Muta, Tsuyoshi

AU - Takashima, Shuichiro

AU - Ito, Yoshikiyo

AU - Shiratsuchi, Motoaki

AU - Choi, Ilseung

AU - Kato, Koji

AU - Takenaka, Katsuto

AU - Iwasaki, Hiromi

AU - Takamatsu, Yasushi

AU - Teshima, Takanori

AU - Akashi, Koichi

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Bortezomib and melphalan have synergistic effects against multiple myeloma (MM) cells. We conducted a pilot study on the combination of bortezomib and high-dose melphalan (Bor-HDM) as a conditioning regimen followed by autologous stem cell transplant (ASCT) in 17 Japanese patients with newly diagnosed MM, in comparison with a historical control of patients who received high-dose melphalan (HDM) only followed by ASCT. Nine patients received a single dose of bortezomib 1.3 mg/m2 on day -1 in combination with melphalan 100 mg/m2 on days -3 and -2 (Bor1-HDM), and eight received two doses of bortezomib 1.3 mg/m2 on days -4 and -1 (Bor2-HDM) in combination with HDM. Engraftment of autologous peripheral blood stem cells and regimen-related toxicities (RRT) were comparable among the HDM and Bor-HDM groups. Probability of upgrading from a less than very good partial response (VGPR) to VGPR after ASCT was approximately two times higher in the Bor-HDM group than in the HDM group. However, we observed no significant differences in engraftment, RRT, and response rates between the Bor1-HDM and Bor2-HDM groups. The present study showed that concurrent administration of at least two doses of bortezomib in combination with HDM can be safe in Japanese patients. Additional large prospective randomized trials are required to address the optimal dosages and schedules of bortezomib administration, as well as the efficacy of the Bor-HDM conditioning regimen for ASCT.

AB - Bortezomib and melphalan have synergistic effects against multiple myeloma (MM) cells. We conducted a pilot study on the combination of bortezomib and high-dose melphalan (Bor-HDM) as a conditioning regimen followed by autologous stem cell transplant (ASCT) in 17 Japanese patients with newly diagnosed MM, in comparison with a historical control of patients who received high-dose melphalan (HDM) only followed by ASCT. Nine patients received a single dose of bortezomib 1.3 mg/m2 on day -1 in combination with melphalan 100 mg/m2 on days -3 and -2 (Bor1-HDM), and eight received two doses of bortezomib 1.3 mg/m2 on days -4 and -1 (Bor2-HDM) in combination with HDM. Engraftment of autologous peripheral blood stem cells and regimen-related toxicities (RRT) were comparable among the HDM and Bor-HDM groups. Probability of upgrading from a less than very good partial response (VGPR) to VGPR after ASCT was approximately two times higher in the Bor-HDM group than in the HDM group. However, we observed no significant differences in engraftment, RRT, and response rates between the Bor1-HDM and Bor2-HDM groups. The present study showed that concurrent administration of at least two doses of bortezomib in combination with HDM can be safe in Japanese patients. Additional large prospective randomized trials are required to address the optimal dosages and schedules of bortezomib administration, as well as the efficacy of the Bor-HDM conditioning regimen for ASCT.

UR - http://www.scopus.com/inward/record.url?scp=84884672057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884672057&partnerID=8YFLogxK

U2 - 10.1007/s12185-013-1402-0

DO - 10.1007/s12185-013-1402-0

M3 - Article

C2 - 23877150

AN - SCOPUS:84884672057

VL - 98

SP - 337

EP - 345

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -